Nuformix PLC Appointment of Non-Executive Director (1967H)
02 December 2020 - 6:00PM
UK Regulatory
TIDMNFX
RNS Number : 1967H
Nuformix PLC
02 December 2020
Nuformix plc
Appointment of Madeleine Kennedy as Non-Executive Director
Cambridge, UK - 2 December 2020: Nuformix plc (LSE:NFX;
"Nuformix", the "Company" or the "Group"), a drug re-purposing
specialist, is pleased to announce that Madeleine ("Maddy")
Kennedy, FCCA, will join the Board of Nuformix as a Non-Executive
Director with immediate effect. Maddy will be appointed as Chair of
the Audit Committee.
Maddy is currently CFO and Board Director of Concepta PLC and
CFO of CFO4Growth Limited. She has previously acted as interim CFO
for Ieso Digital Health Ltd and PsiOxus Therapeutics Ltd, was CFO
for Lab21 Limited and Finance Director at Alliance Pharma plc,
taking it through its IPO. She specialises in growing life science
businesses and has more than 20 years' experience in the sector,
both in public and private companies.
Dr Chris Blackwell, Executive Chairman, commented:
"It's a pleasure for us to welcome Maddy to the Board. Maddy's
knowledge and experience will be extremely valuable as the Company
moves forward with its near-term strategic priorities. "
Commenting on her appointment, Maddy Kennedy said:
"I am delighted to be joining the Board of Nuformix and look
forward to working with the Board and the team, to achieve its
strategic objectives."
No further information is required to be disclosed pursuant to
LR 9.6.13R of the UK Listing Rules.
The person responsible for arranging the release of this
announcement on behalf of the Company is Dr Chris Blackwell,
Executive Chairman.
Enquiries:
Nuformix plc
Dr Chris Blackwell, Executive Chairman
Fleur Wood, Investor Relations
Email: fleur.wood@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About Nuformix
Nuformix is a pharmaceutical development company focused on
unlocking the therapeutic potential and value of known drugs to
develop new novel medicines which provide therapeutic and
commercial advantages to the currently available drug form.
Nuformix's model of repurposing drugs utilises many technologies
but is focussed on its acknowledged expertise in the use of
cocrystal technology through which the Group has developed and
patented novel forms of small molecules. Its platform is not
therapy-specific but instead has broad application across a wide
range of indications. Using its technology, the Group is developing
proprietary medicines for its own development pipeline and in
partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX. For more information please
visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEANAFEDFEFFA
(END) Dow Jones Newswires
December 02, 2020 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024